An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Last updated: June 25, 2025
Sponsor: NGM Biopharmaceuticals, Inc
Overall Status: Active - Recruiting

Phase

2

Condition

Rectal Cancer

Cancer

Colon Cancer

Treatment

NGM120 Q4W

Placebo given

NGM120 Q8W

Clinical Study ID

NCT07033026
120-CX-202
  • Ages > 18
  • All Genders

Study Summary

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Documented active diagnosis of colorectal cancer.

  2. Cachexia defined by Fearon criteria of weight loss.

  3. Signed informed consent.

Exclusion

Exclusion Criteria:

  1. Current active reversible causes of decreased food intake.

  2. Receiving tube feedings or parenteral nutrition at the time of Screening orRandomization.

  3. Have cachexia caused by other reasons.

Study Design

Total Participants: 136
Treatment Group(s): 3
Primary Treatment: NGM120 Q4W
Phase: 2
Study Start date:
June 01, 2025
Estimated Completion Date:
December 31, 2027

Study Description

Evaluation of Efficacy, Safety and Tolerability of NGM120 in a Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Participants with Colorectal Cancer who have Cancer Cachexia

Connect with a study center

  • NGM Clinical Study Site

    Laredo, Texas 78041
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.